

CHAPTER - 10

Bibliography

- Adamson AW and Gast AP, Physical Chemistry of Surfaces, John Wiley and Sons, New York, USA, 1997.
- Akpınar O, Bozkurt A, Acartürk E, and Şeydaoğlu G, “A New Index (CHOLINDEX) in Detecting Coronary Artery Disease Risk,” *The Anatolian Journal of Cardiology*, 13(2013)315-319.
- Alam MA, Al-Jenoobi FI and Al-mohizea AM, “Commercially Bioavailable Proprietary Technologies and their Marketed Products,” *Drug Discovery Today*, (2013)1-14.
- Alhalaweh A, Roy L, Rodríguez-Hornedo N, and Velaga SP, “pH-Dependent Solubility of Indomethacin–Saccharin and Carbamazepine–Saccharin Cocrystals in Aqueous Media,” *Molecular Pharmaceutics*, 9(2012)2605-2612.
- Almarsson O, Hickey MB, Peterson ML, ZaWorotko MJ, Moulton B, and Rodriguez-Hornedo N, US Patent No. 7927613 B2, 2011.
- Amidon GL, Lennernas H, Shah VP, Crison JR, “A Theoretical Basis for a Biopharmaceutic Drug Classification: the Correlation of In vitro Drug Product Dissolution and In vivo Bioavailability,” *Pharmaceutical Research*, 12(1995)413-420.
- Ammar HO, Salama HA, and Mahmoud AA, “Implication of Inclusion Complexation of Glibenclamide in Cyclodextrin–Polymer Systems on its Dissolution, Stability and Therapeutic Efficacy,” *International Journal of Pharmaceutics*, 320(2006)53-57.
- Asbahr ACC, Franco L, Barison A, Silva CWP, Ferraz HG, and Rodrigues LNC, “Binary and Ternary Inclusion Complexes of Finasteride in HPBCD and Polymers: Preparation and Characterization,” *Bioorganic & Medicinal Chemistry*, 17(2009)2718-2723.
- Athimoolam S and Rajaram RK, “Dinicotinium Sulfate,” *Acta Crystallographica*, 61(2005)2764-2767.
- Augustijns P, Brouwers J, and Brewster ME, “Supersaturating Drug Delivery Systems: the Answer to Solubility-Limited Oral Bioavailability?,” *Journal of Pharmaceutical Sciences*, 98(2009)2549-2572.

- Aulton ME, *Pharmaceutics: The Science of Dosage Form*, Churchill Livingstone, London, UK, 1998.
- Baert L, Klooster GV, Dries W, Francois M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Remoortere PV, Kraus G, Wigerinck P, and Rosier J, "Development of a Long-acting Injectable Formulation with Nanoparticles of Rilpivirine (TMC278) for HIV Treatment," *European Journal of Pharmaceutics and Biopharmaceutics*, 72(2009)502-508.
- Bali V, Ali M, and Ali J, "Study of Surfactant Combinations and Development of a Novel Nanoemulsion for Minimising Variations in Bioavailability of Ezetimibe," *Colloids and Surfaces B: Biointerfaces*, 76(2010)410-420.
- Bali V, Ali M, and Ali J, "Nanocarrier for the Enhanced Bioavailability of a Cardiovascular Agent: In vitro, Pharmacodynamic, Pharmacokinetic and Stability Assessment," *International Journal of Pharmaceutics*, 403(2011)46-56.
- Bandyopadhyay S, Katare OP, and Singh B, "Optimized Self Nano-Emulsifying Systems of Ezetimibe with Enhanced Bioavailability Potential using Long Chain and Medium Chain Triglycerides," *Colloids and Surfaces B: Biointerfaces*, 100(2012)50-61.
- Barishansky N, Childs SL, and Lingireddy SR, WIPO Patent No. 2012116349 A2, 2012.
- Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, and Veltri EP, "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies," *Clinical Therapeutics*, 23(2001)1209-1230.
- Bernini A, Spiga O, Ciutti A, Scarselli M, Bottoni G, Mascagni P, and Niccolai N, "NMR Studies of the Inclusion Complex between Beta-Cyclodextrin and Paroxetine," *European Journal of Pharmaceutical Sciences*, 22(2004)445-450.
- Berry DJ, Seaton CC, Clegg W, Harrington RW, Coles SJ, Horton PN, Hursthouse MB, Storey R, Jones W, Friscic T, and Blagden N, "Applying Hot-Stage Microscopy to Co-Crystal Screening: a Study of Nicotinamide with Seven Active Pharmaceutical Ingredients," *Crystal Growth & Design*, 8(2008)1697-1712.
- Bevill MJ and Schultheiss N, US Patent No. 20140073674 A1, 2014.
- Blagden N, de Matas M, Gavan PT, and York P, "Crystal Engineering of Active Pharmaceutical Ingredients to Improve Solubility and Dissolution Rates," *Advanced Drug Delivery Reviews*, 59(2007)617-630.
- Brahmankar DM and Jaiswal SB, *Biopharmaceutics & Pharmacokinetics A Treatise*, Vallabh Prakashan, New Delhi, India, 2012.

- Bressolle F, Bromet-Petit M. and Audran M, "Validation of Liquid Chromatographic and Gas Chromatographic Methods Applications to Pharmacokinetics," *Journal of Chromatography B*, 686(1996)3-10.
- Brewster M, "Registration Experiences with Hydroxypropyl- β -cyclodextrin," Pre-conference Workshop, Cyclodextrins and Cyclodextrin Derivatives as Pharmaceutical Excipients: Toxicological and Regulatory Issues, Reykjavik, Iceland, June 2nd 2012.
- Buckton G and Beezer AE, "The Relationship between Particle-Size and Solubility," *International Journal of Pharmaceutics*, 82(1992)7-10.
- Carrier RL, Miller LA, and Ahmed I, "The Utility of Cyclodextrins for Enhancing Oral Bioavailability," *Journal of Controlled Release*, 123(2007)78-99.
- Catapano AL, "Ezetimibe: A Selective Inhibitor of Cholesterol Absorption," *European Heart Journal Supplements*, 3(2001)6-10.
- Cerdeira AM, Mazzotti M, and Gande B, "Miconazole Nanosuspensions: Influence of Formulation Variables on Particle Size Reduction and Physical Stability," *International Journal of Pharmaceutics*, 396(2012)210-218.
- Childs SL, Kandi P, and Lingireddy SR, "Formulation of a Danazol Cocrystal with Controlled Supersaturation Plays an Essential Role in Improving Bioavailability," *Molecular Pharmaceutics*, 10(2013)3112-3127.
- Chowdary KPR and Srinivas SJ, "Influence of Hydrophilic Polymers on Celecoxib Complexation with Hydroxypropyl- β -Cyclodextrin," *AAPS PharmSciTech*, 7(2006)1-6.
- Clarke H, Kapildev A, Kavuru P, Marshall L, Ong TT, Pujari T, Shytle RD, and Zaworotko M, WIPO Patent No. 2008153945 A3, 2009.
- Cogent diagnostic kit guidelines (Span Diagnostics Ltd., Surat, India).
- Davidson MH and Toth PP, "Comparative Effects of Lipid-Lowering Therapies," *Progress in Cardiovascular Diseases*, 47(2004)73-104.
- Deng Z, Xu S, and Li S, "Understanding a Relaxation Behaviour in a Nanoparticle Suspension for Drug Delivery Applications," *International Journal of Pharmaceutics*, 351(2008)236-243.
- Desiraju GR, *Crystal Engineering: the Design of Organic Solids*, Elsevier, Amsterdam, Netherlands, 1989.
- Desiraju GR, "Supramolecular Synthons in Crystal Engineering—a New Organic Synthesis," *Angewandte Chemie International Edition in English*, 34(1995)2311-2327.

- Dhumal RS, Biradar SV, Paradkar AR, and York P, "Particle Engineering using Sonocrystallization: Salbutamol Sulphate for Pulmonary Delivery," *International Journal of Pharmaceutics*, 368(2009)129-137.
- Dixit RP and Nagarsenker MS, "Self-Nanoemulsifying Granules of Ezetimibe: Design, Optimization and Evaluation," *European Journal of Pharmaceutical Sciences*, 35(2008)183-192.
- Douroumis D and Fahr A, "Stable Carbamazepine Colloidal Systems using the Cosolvent Technique," *European Journal of Pharmaceutical Sciences*, 30(2007)367-374.
- Duggirala NK, Perry ML, Almarsson O and Zaworotko MJ, "Pharmaceutical Cocrystals: along the Path to Improved Medicines," *Chemical Communications*, 52(2016)640-655.
- Duran-Meras I, Pena AM, Salinas F, and Caceres IR, "Spectrofluorimetric Determination of Nalidixic Acid Based on Host-Guest Complexation with γ -Cyclodextrin," *Analyst*, 119(1994)1215-1219.
- Eerdenbrugh BV, Froyen L, Humbeeck JV, Martens JA, Augustijns P, and den Mooter GV, "Drying of Crystalline Drug Nanosuspensions-the Importance of Surface Hydrophobicity on Dissolution Behavior upon Redispersion," *European Journal of Pharmaceutical Sciences*, 35(2008a)127-135.
- Eerdenbrugh BV, Mooter GV, and Augustijns P, "Top-down Production of Drug Nanocrystals: Nanosuspension Stabilization, Miniaturization and Transformation into Solid Products," *International Journal of Pharmaceutics*, 364(2008b)64-75.
- Eerdenburgh VB, Vermant J, Martens JA, Froyen L, Humbeeck VJ, Augustijns P, and Mooter VG, "A Screening Study of Surface Stabilization During the Production of Drug Nanocrystals," *Journal of Pharmaceutical Sciences*, 98(2009)2091-2103.
- EMA Guideline on the Investigation of Bioequivalence. London, 20 January 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Last accessed on 10 October 2015.
- Folkers G, van de Waterbeem H, Lennernäs H, Artursson P, Mannhold R, and Kubinyi H, *Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability (Methods and Principles in Medicinal Chemistry)*, Wiley-VCH, Weinheim, Germany, 2003.
- Frank M, Haeberle H, Henry M, Pachur T, Santagostino M, Stertz U, Trebing T, and Werthmann U, WIPO Patent No. 2012045803 A1, 2012.

- Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, and Nightingale JAS, "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview," *Molecular Pharmaceutics*, 5(2008)1003-1019.
- Gagniere E, Mangin D, Puel F, Rivoire A, Monnier O, Garcia E, and Klein JP, "Formation of Co-crystals: Kinetic and Thermodynamic Aspects," *Journal of Crystal Growth*, 311(2009a)2689-2695.
- Gagniere E, Mangin D, Puel F, Bebon C, Klein JP, Monnier O, and Garcia E, "Cocrystal Formation in Solution: In situ Solute Concentration Monitoring of the Two Components and Kinetic Pathways," *Crystal Growth & Design*, 9(2009b)3376-3383.
- Gaikwad P and Bhoir S, "Optimized Conditions for the Enzymatic Hydrolysis of Glucuronidated Phase II Ezetimibe Metabolite in Human Plasma," *International Journal of Pharmacy and Pharmaceutical Sciences*, 5(2013)753-757.
- Gaikwad P, Bhagwat A, and Bhoir S, "HPLC with UV and Mass Spectrometric Detection for Quantifying Total Ezetimibe in Human Plasma: Validation and Application in Pharmacokinetic Study," *International Journal of Biological & Pharmaceutical Research*, 4(2013)216-224.
- Gao L, Liu G, Kang J, Niua M, Wanga Z, Wang H, Maa J, and Wang X, "Paclitaxel Nanosuspensions Coated with P-gp Inhibitory Surfactants: I. Acute Toxicity and Pharmacokinetics Studies," *Colloids and Surfaces B: Biointerfaces*, 111(2013)277-281.
- Gao L, Zhang D, Chen M, Zheng T, and Wang SF, "Preparation and Characterization of an Oridonin Nanosuspension for Solubility and Dissolution Rate Enhancement," *Drug Development and Industrial Pharmacy*, 33(2007)1332-1339.
- Gao L, Zhang D, and Chen M, "Drug Nanocrystals for the Formulation of Poorly Soluble Drugs and its Application as a Potential Drug Delivery System," *Journal of Nanoparticle Research*, 10(2008)845-862.
- Gao Y, Zu H and Zhang J, "Enhanced Dissolution and Stability of Adefovir Dipivoxil by Cocrystal Formation," *Journal of Pharmacy and Pharmacology*, 63(2011)483-490.
- Gao Y, Gao J, Liu Z, Kan H, Zu H, Sun W, Zhang J, and Qian S, "Coformer Selection Based on Degradation Pathway of Drugs: A Case Study of Adefovir Dipivoxil Saccharin and Adefovir Dipivoxil-Nicotinamide Cocrystals," *International Journal of Pharmaceutics*, 438(2012)327-335.
- Garcia-Calvo M, Lisnock JM, Bull HG, Hawes BE, Burnett DA, Braunc MP, Crona JH, Davis HR, Dean DC (Jr.), Detmers PA, Graziano MP, Hughes M, MacIntyre DE, Ogawa A, O'Neill KA, Iyer SPN, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, and Thornberry

- NA, "The Target of Ezetimibe is Niemann–Pick C1-Like 1 (NPC1L1)," *Proceedings of the National Academy of Sciences*, 102(2005)8132-8137.
- Garekani HA, Sadeghi F, Badiee A, Mostafa SA, and Rajabi-Siahboomi AR, "Crystal Habit Modifications of Ibuprofen and their Physicomechanical Characteristics," *Drug Development and Industrial Pharmacy*, 27(2001)803-809.
- Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, and Murphy A, "Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries," *Current Problems in Cardiology*, 35(2010)72-115.
- Ge X, Huang Z, Tian S, Huang Y, and Zeng C, "Complexation of Carbendazim with Hydroxypropyl- β -Cyclodextrin to Improve Solubility and Fungicidal Activity," *Carbohydrate Polymers*, 89(2012)208-212.
- George M and Ghosh I, "Identifying the Correlation between Drug/Stabilizer Properties and Critical Quality Attributes (CQAs) of Nanosuspension Formulation Prepared by Wet Media Milling Technology," *European Journal of Pharmaceutical Sciences*, 48(2013)142-152.
- Ghosh I, Bose S, Vippagunta R, and Harmon F, "Nanosuspension for Improving the Bioavailability of a Poorly Soluble Drug and Screening of Stabilizing Agents to Inhibit Crystal Growth," *International Journal of Pharmaceutics*, 409(2011)260-268.
- Ghosh I, Schenck D, Bose S, and Ruegger C, "Optimization of Formulation and Process Parameters for the Production of Nanosuspension by Wet Media Milling Technique: Effect of Vitamin E TPGS and Nanocrystal Particle Size on Oral Absorption," *European Journal of Pharmaceutical Sciences*, 47(2012)718-728.
- Giliyar C, Fickstad DT, and Tyavanagimatt S, "Challenges and Opportunities in Oral Delivery of Poorly-Soluble Drugs," *Drug Delivery Technology*, 6(2006)57-63.
- Gomez-Orellana I, "Strategies to Improve Oral Drug Bioavailability," *Expert Opinion on Drug Delivery*, 2(2005)419-433.
- Goud NR, Gangavaram S, Suresh K, Pal S, Manjunatha SG, Nambiar S, and Nangia A, "Novel Furosemide Cocrystals and Selection of High Solubility Drug Forms," *Journal of Pharmaceutical Sciences*, 101(2012)664-680.
- Grande F, Amafuzio DS, and Wada S, "Cholesterol Measurement in Serum and in Plasma," *Clinical Chemistry*, 7(1964)619-626.

- Guidance for 510(k)s on Cholesterol Tests for Clinical Laboratory, Physicians' Office Laboratory and Home Use. Available from: <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094140.htm>. Last accessed on 10 October 2015.
- Guidance for industry: regulatory classification of pharmaceutical co-crystals, Food and Drug Administration, Silver Spring, MD, 2011. Available from: <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM281764.pdf>. Last accessed on 08 October, 2015.
- Gulsun T, Gursoy RN, and Oner L, "Design and Characterization of Nanocrystal Formulations Containing Ezetimibe," *Chemical and Pharmaceutical Bulletin*, 59(2011)41-45.
- Guntupalli S, Ray UK, Murali N, Gupta PB, Kumar VJ, Satheesh D, and Islam A, "Identification, Isolation and Characterization of Process Related Impurities in Ezetimibe," *Journal of Pharmaceutical and Biomedical Analysis*, 88(2014)385-390.
- Guo Y, Luo J, Tan S, Otieno BO, and Zhang Z, "The Applications of Vitamin E TPGS in Drug Delivery," *European Journal of Pharmaceutical Sciences*, 49(2013)175-186.
- Guo Z, Zhang M, Li H, Wang J, and Kougoulos E, "Effect of Ultrasound on Antisolvent Crystallization Process," *Journal of Crystal Growth*, 273(2005)555-563.
- Gursoy RN and Benita S, "Self-Emulsifying Drug Delivery Systems (SEDDS) for Improved Oral Delivery of Lipophilic Drugs," *Biomedicine & Pharmacotherapy*, 58(2004)173-182.
- Hammond RB, Pencheva K, Roberts KJ, and Auffret T, "Quantifying Solubility Enhancement due to Particle Size Reduction and Crystal Habit Modification: Case Study of Acetyl Salicylic Acid," *Journal of Pharmaceutical Sciences*, 96(2007)1967-1973.
- Heek MV, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, and Davis HR(Jr), "In vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey Through the Identification of the Active Metabolites of SCH48461," *Journal of Pharmacology and Experimental Therapeutics*, 283(1997)157-163.
- Heek MV, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, and Davis HR(Jr), "Comparison of the Activity and Disposition of the Novel Cholesterol Absorption Inhibitor, SCH58235, and its Glucuronide, SCH60663," *British Journal of Pharmacology*, 129(2000)1748-1754.
- Heek MV, Compton DS, and Davis HR, "The Cholesterol Absorption Inhibitor, Ezetimibe, Decreases Diet Induced Hypercholesterolemia in Monkeys," *European Journal of Pharmacology*, 415(2001)79-84.

Chapter 10 - Bibliography

Higuchi T and Connors KA, "Phase Solubility Techniques," *Advances in Analytical Chemistry and Instrumentation*, 4(1965)117-212.

Hintz RJ and Johnson KC, "The Effect of Particle Size Distribution on Dissolution Rate and Oral Absorption," *International Journal of Pharmaceutics*, 51(1989)9-17.

Hirlekar RS, Sonawane SN, and Kadam VJ, "Studies on the Effect of Water-Soluble Polymers on Drug-Cyclodextrin Complex Solubility," *AAPS PharmSciTech*, 10(2009)858-863.

<http://cellbone.com/Ascorbic2.htm>. Last accessed on 01 March 2016.

<http://legacy.statease.com/dex8files/manual/dx/DX8-03A-TwoLevel-P1.pdf>. Last accessed on 01 January 2016.

<http://rarediseases.org/rare-diseases/familial-hypercholesterolemia/>. Last accessed on 01 October 2015.

<http://scienceline.ucsb.edu/getkey.php?key=275>. Last accessed on 01 October 2015.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021445s020s0211bl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=582e1593-1e6c-4ce8-8bae-134fbc3a66f0. Last accessed on 06 October 2015.

http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf. Last accessed on 06 October 2015.

http://www.acciusa.com/pdfs/MSDS_ns/400535m.pdf. Last accessed on 09 December 2015.

<http://www.dissolution.com/ddg/showthread.php?1329-Dissolution-of-ezetimibe-tablets>. Last accessed on 01 October 2015.

<http://www.dissolution.com/ddg/showthread.php?145-USP-change-to-0-01N-HCl>. Last accessed on 01 October 2015.

<http://www.drugbank.ca/drugs/DB00973>. Last accessed on 06 October 2015.

<http://www.drug-dissolution-testing.com/?p=233>. Last accessed on 06 October 2015.

<http://www.drugs.com/niacin.html>. Last accessed on 12 February 2016.

<http://www.itl.nist.gov/div898/handbook/pri/section3/pri33.htm>. Last accessed on 01 January 2016.

<http://www.itl.nist.gov/div898/handbook/pri/section3/pri3361.htm>. Last accessed on 01 January 2016.

<http://www.itl.nist.gov/div898/handbook/pri/section3/pri3362.htm>. Last accessed on 01 January 2016.

<http://www.itl.nist.gov/div898/handbook/pri/section3/pri3363.htm>. Last accessed on 01 January 2016.

http://www.nicnas.gov.au/_data/assets/pdf_file/0016/10393/STD1056FR.pdf. Last accessed on 01 October 2015.

<http://www.particlesciences.com/news/technical-briefs/2011/biopharmaceutical-classification-system.html>. Last accessed on 15 November 2015.

<http://www.pharmainfo.net/files/groupsimages/BioavailabilitySolvedProblems.pdf>. Last accessed on 21 July 2015.

<http://www.pharmtech.com/using-tocophersolan-drug-delivery>. Last accessed on 17 February 2016.

<http://www.scbt.com/datasheet-205768-nicotinic-acid.html>. Last accessed on 12 February 2016.

<http://www.tpgs.com/>. Last accessed on 17 February 2016.

<https://pubchem.ncbi.nlm.nih.gov/compound/nicotinamide#section=Boiling-Point>. Last accessed on 12 February 2016.

https://pubchem.ncbi.nlm.nih.gov/compound/nicotinic_acid#section=Chemical-Vendors. Last accessed on 12 February 2016.

<https://www.drugs.com/drp/nicotinamide.html>. Last accessed on 12 February 2016.

<https://www.fsc.go.jp/english/evaluationreports/foodadditive/l-ascorbic.pdf>. Last accessed on 01 March 2016.

<https://www.quora.com/What-is-the-pH-of-distilled-water>. Last accessed on 17 March 2016.

https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/General_Information/2/biofiles_issue12.pdf. Last accessed on 10 October 2015.

Ige PP, Baria RK, and Gattani SG, "Fabrication of Fenofibrate Nanocrystals by Probe Sonication Method for Enhancement of Dissolution Rate and Oral Bioavailability," *Colloids and Surfaces B: Biointerfaces*, 108(2013)366-373.

Inoue Y, Yoshimura S, Tozuka Y, Moribe K, Kumamoto T, Ishikawa T and Yamamoto K, "Application of Ascorbic Acid 2-Glucoside as a Solubilizing Agent for Clarithromycin: Solubilization and Nanoparticle Formation," *International Journal of Pharmaceutics*, 331(2007)38-45.

Jadhav P, Petkar B, Pore Y, Kulkarni A, and Burade K, "Physicochemical and Molecular Modeling Studies of Cefixime–L-Arginine–Cyclodextrin Ternary Inclusion Compounds," *Carbohydrate Polymers*, 98(2013)1317-1325.

- Jayasagar G, Kumar MK, Chandrasekhar K, Prasad SP and Rao YM, "Validated HPLC Method for the Determination of Celecoxib in Human Serum and its Application in a Clinical Pharmaceutical Study," *Pharmazie*, 57(2002)619-621.
- Jayasankar A, Somwangthanaroj A, Shao ZJ, and Rodriguez-Hornedo N, "Cocrystal Formation during Cogrinding and Storage is Mediated by Amorphous Phase," *Pharmaceutical Research*, 23(2006)2381-2392.
- Jug M, Kosalec I, Maestrelli F, and Mura P, "Analysis of Triclosan Inclusion Complexes with β -Cyclodextrin and its Water-Soluble Polymeric Derivative," *Journal of Pharmaceutical and Biomedical Analysis*, 54(2011)1030-1039.
- Jug M, Mennini N, Kövér KE, and Mura P, "Comparative Analysis of Binary and Ternary Cyclodextrin Complexes with Econazole Nitrate in Solution and in Solid State," *Journal of Pharmaceutical and Biomedical Analysis*, 91(2014)81-91.
- Kaartama R, Turunen E, Toljamo K, Kokki H, Lehtonen M, Ranta V, Savolainen J, Järvinen K, and Jarho P, "The Effect of Hydroxypropyl-beta-cyclodextrin and Sucrose on the Sublingual Absorption of Midazolam in Rabbits," *European Journal of Pharmaceutics and Biopharmaceutics*, 81(2012)178-183.
- Katritzky AR, Jain R, Lomaka A, Petrukhin R, Maran U, and Karelson M, "Perspective on the Relationship between Melting Points and Chemical Structure," *Crystal Growth & Design*, 1(2001)261-265.
- Kavuru P, Aboarayas D, Arora KK, Clarke HD, Kennedy A, Marshall L, Ong TT, Perman J, Pujari T, Wojtas L, and Zaworotko MJ, "Hierarchy of Supramolecular Synthons: Persistent Hydrogen Bonds Between Carboxylates and Weakly Acidic Hydroxyl Moieties in Cocrystals of Zwitterions," *Crystal Growth & Design*, 10(2010)3568-3584.
- Kawakami K, "Modification of Physicochemical Characteristics of Active Pharmaceutical Ingredients and Application of Supersaturatable Dosage Forms for Improving Bioavailability of Poorly Absorbed Drugs," *Advanced Drug Delivery Reviews*, 64(2012)480-495.
- Kesisoglou F, Panmai S, and Wu Y, "Nanosizing — Oral Formulation Development and Biopharmaceutical Evaluation," *Advanced Drug Delivery Reviews*, 59(2007)631-644.
- Kilinkissa OEY, "Physical Chemical Properties of Selected Pharmaceutical Co-Crystals," Ph.D. Thesis, Cape Peninsula University of Technology, Cape Town, South Africa, 2014.
- Kosoglou T, Statkevich P, Johnson-Levonos AO, Paolini JF, Bergman, AJ, and Alton KB, "Ezetimibe: a Review of its Metabolism, Pharmacokinetics and Drug Interaction," *Journal of Clinical Pharmacology*, 44(2005)467-494.

- Kumar MP, Rao YM, and Apte S, "Formulation of Nanosuspensions of Albendazole for Oral Administration," *Current Nanoscience*, 4(2008)53-58.
- Labhassetwar V, Deshmukh SV, and Dorle AK, "Studies on Some Crystalline Forms of Ibuprofen," *Drug Development and Industrial Pharmacy*, 19(1993)631-641.
- Lafta MA, "A Comparative Study for Some Atherogenic Indices in Sera of Myocardial infarction, Ischemic Heart Disease Patients and Control," *Journal of Natural Sciences Research*, 4(2014)96-102.
- Lai SL, Guo JY, Petrova V, Ramanath G, and Allen LH, "Size-Dependent Melting Properties of Small Tin Particles: Nanocalorimetric Measurements," *Physical Review Letters*, 77(1996)99-102.
- Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig, T, Vergnault G, and Spahn-Langgtuh H, "Nanosuspension Formulations for Low Soluble Drugs: Pharmacokinetic Evaluation Using Spiranolactone as Model Compound," *Drug Development and Industrial Pharmacy*, 31(2005)319-329.
- Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ, "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings," *Advanced Drug Delivery Reviews*, 23(1976)3-25.
- Liu G, Zhang D, Jiao Y, Guoa H, Zheng D, Jia L, Duana C, Liu Y, Tian X, Shen J, Li C, Zhang Q, and Lou H, "In vitro and In vivo Evaluation of Riccardin D Nanosuspensions with Different Particle Size," *Colloids and Surfaces B: Biointerfaces* 102(2013)620-626.
- Liu R, *Water-Insoluble Drug Formulation*, CRC Press, Taylor & Francis Group, USA, 2008.
- Liu Y, Huang L, and Liu F, "Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer," *Molecular Pharmaceutics*, 7(2010)863-869.
- Loftsson T and Brewster ME, "Pharmaceutical Applications of Cyclodextrins: Basic Science and Product Development," *Journal of Pharmacy and Pharmacology*, 62(2010)1607-1621.
- Loftsson T and Brewster ME, "Cyclodextrins as Functional Excipients: Methods to Enhance Complexation Efficiency," *Journal of Pharmaceutical Sciences*, 101(2012)3019-3032.
- Loftsson T, Frikdriksdóttir H, Sigurkdardóttir AM, and Haruhisa U, "The Effect of Water-Soluble Polymers on Drug-Cyclodextrin Complexation," *International Journal of Pharmaceutics*, 110(1994)169-177.
- Loftsson T, Jarho P, Másson M and Järvinen T, "Cyclodextrins in Drug Delivery," *Expert Opinion on Drug Delivery*, 2(2005)335-351.

- Loh GOK, Tan YTF, and Peh KK, "Effect of HPMC Concentration on β -Cyclodextrin Solubilization of Norfloxacin," *Carbohydrate Polymers*, 101(2014)505-510.
- Lu J and Rohani S, "Preparation and Characterization of Theophylline-Nicotinamide Cocrystal," *Organic Process Research & Development*, 13(2009)1269-1275.
- Makhlof A, Miyazaki Y, Tozuka Y, and Takeuchi H, "Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method," *International Journal of Pharmaceutics*, 357(2008)280-285.
- Martin CRL, "Crystal Engineering Approaches to Controlling the Formation of Molecular Complexes and their Polymorphs," Ph.D. Thesis, University of Glasgow, Scotland, UK, 2011.
- Merisko-Liversidge E, Liversidge GG, and Cooper ER, "Nanosizing: a Formulation Approach for Poorly-Water-Soluble Compounds," *European Journal of Pharmaceutical Sciences*, 18(2003)113-120.
- Merisko-Liversidge E and Liversidge GG, "Nanosizing for Oral and Parenteral Drug Delivery: A Perspective on Formulating Poorly-Water Soluble Compounds Using Wet Media Milling Technology," *Advanced Drug Delivery Reviews*, 63(2011)427-440.
- Miranda JCD, Martins TEA, Veiga F, and Ferraz HG, "Cyclodextrins and Ternary Complexes: Technology to Improve Solubility of Poorly Soluble Drugs," *Brazilian Journal of Pharmaceutical Sciences*, 47(2011)665-681.
- Mishra PR, Shaal LA, Müller RH, and Keck CM, "Production and Characterization of Hesperetin Nanosuspensions for Dermal Delivery," *International Journal of Pharmaceutics*, 371(2009)182-189.
- Misiuk W and Zalewska M, "Investigation of Inclusion Complex of Trazodone Hydrochloride with Hydroxypropyl- β -Cyclodextrin," *Carbohydrate Polymers*, 77(2009)482-488.
- Misiuk W and Zalewska M, "Spectroscopic Investigations on the Inclusion Interaction between Hydroxypropyl- β -Cyclodextrin and Bupropion," *Journal of Molecular Liquids*, 159(2011)220-225.
- Moribe K, Limwikrant W, Higashi K and Yamamoto K, "Drug Nanoparticle Formulation using Ascorbic Acid Derivatives," *Journal of Drug Delivery*, 2011(2011)1-9.
- Möschwitzer JP, "Drug Nanocrystals in the Commercial Pharmaceutical Development Process," *International Journal of Pharmaceutics*, 453(2013)142-156.
- Mosharraf M and Nyström C, "The Effect of Particle Size and Shape on the Surface Specific Dissolution Rate of Microsized Practically Insoluble Drugs," *International Journal of Pharmaceutics*, 122(1995)35-47.

- Müller RH and Peters K, "Nanosuspensions for the Formulation of Poorly Soluble Drugs: I. Preparation by a Size-Reduction Technique," *International Journal of Pharmaceutics*, 160(1998)229-237.
- Müller RH, Jacobs C, and Kayser O, "Nanosuspensions as Particulate Drug Formulations in therapy: Rationale for Development and What We Can Expect for the Future," *Advanced Drug Delivery Reviews*, 47(2001)3-19.
- Müllers KC, "Solving the Matter Crystal Engineering and Particle Design of Poorly Soluble Drugs via Rapid Expansion of Supercritical Solutions," Ph.D. Thesis, University of Tübingen, Tübingen, Germany, 2015.
- Mulye SP, Jamadar SA, Karekar PS, Pore YV, and Dhawale SC, "Improvement in Physicochemical Properties of Ezetimibe using a Crystal Engineering Technique," *Powder Technology*, 222(2012)131-138.
- Muto N, Suga S, Fujii K, Goto K, and Yamamoto I, "Formation of a Stable Ascorbic Acid 2-Glucoside by Specific Transglucosylation with Rice Seed α -Glucosidase," *Agricultural and Biological Chemistry*, 54(1990)1697-1703.
- Nauha E, "Crystalline Forms of Selected Agrochemical Actives: Design and Synthesis of Cocrystals," Ph.D. Thesis, University of Jyväskylä, Jyväskylä, Finland, 2011.
- Nehm SJ, Rodríguez-Spong B, and Rodríguez-Hornedo N, "Phase Solubility Diagrams of Cocrystals are Explained by Solubility Product and Solution Complexation," *Crystal Growth & Design*, 6(2006)592-600.
- Nikolic V, Stankovic M, Kapor A, Nikolic L, Cvetkovic D, and Stamenkovic J, "Allylthiosulfinate/ β -Cyclodextrin Inclusion Complex: Preparation, Characterization and Microbiological Activity," *Pharmazie*, 59(2004)845-848.
- Niwa T, Miura S, and Danjo K, "Universal Wet-Milling Technique to Prepare Oral Nanosuspension Focused on Discovery and Preclinical Animal Studies – Development of Particle Design Method," *International Journal of Pharmaceutics*, 405(2011)218-227.
- Nogueiras-Nieto L, Sobarzo-Sánchez E, Gómez-Amoza JL, and Otero-Espinar FJ, "Competitive Displacement of Drugs from Cyclodextrin Inclusion Complex by Polypseudorotaxane Formation with Poloxamer: Implications in Drug Solubilization and Delivery," *European Journal of Pharmaceutics and Biopharmaceutics*, 80(2012)585-595.
- Pardeike J and Müller RH, "Nanosuspensions a Promising Formulation for the New Phospholipase A2 Inhibitor PX-18," *International Journal of Pharmaceutics*, 391(2010)322-329.
- Patel J, Sheehan V, and Gurk-Turner C, "Ezetimibe (Zetia): a New Type of Lipid-Lowering Agent," *Proceedings (Baylor University. Medical Center)*, 16(2003)354-358.

- Patel R, Bhimani D, Patel J, and Patel D, "Solid-state Characterization and Dissolution Properties of Ezetimibe–Cyclodextrins Inclusion Complexes," *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 60(2008)241-251.
- Peake KB and Vance JE, "Normalization of Cholesterol Homeostasis by 2-Hydroxypropyl- β -Cyclodextrin in Neurons and Glia from Niemann-Pick C1 (NPC1)-deficient Mice," *Journal of Biological Chemistry*, 287(2012)9290-9298.
- Peltonen L and Hirvonen J, "Pharmaceutical Nanocrystals by Media Milling: Critical Process Parameters, Particle Fracturing and Stabilization Methods," *Journal of Pharmacy and Pharmacology*, 62(2010)1569-1579.
- Ploehn HJ and Russel WB, "Interactions between Colloidal Particles and Soluble Polymers," *Advances in Chemical Engineering*, 15(1990)137-228.
- Porter CJH, Pouton CW, Cuine JF, and Charman WN, "Enhancing Intestinal Drug Solubilisation using Lipid-Based Delivery Systems," *Advanced Drug Delivery Reviews*, 60(2008)673-691.
- Qiao N, Li M, Schlindwein W, Malek N, Davies A, and Gary T, "Pharmaceutical Cocrystals: An Overview," *International Journal of Pharmaceutics*, 419(2011)1-11.
- Raghavan SL, Trividic A, Davis AF, and Hadgraft J, "Crystallization of Hydrocortisone Acetate: Influence of Polymers," *International Journal of Pharmaceutics*, 212(2001)213-221.
- Rahman Z, Agarabi C, Zidan AS, Khan SR, and Khan MA, "Physico-Mechanical and Stability Evaluation of Carbamazepine Cocrystal with Nicotinamide," *AAPS PharmSciTech*, 12(2011)693-704.
- Rajebahadur M, Zia H, Nues A, and Lee C, "Mechanistic Study of Solubility Enhancement of Nifedipine using Vitamin E TPGS or Solutol HS-15," *Drug Delivery*, 13(2006)201-206.
- Ranjit PM, Guntuku G, and Pothineni RB, "New Atherogenic Indices: Assessment of Cardio Vascular Risk in Post Menopausal Dyslipidemia," *Asian Journal of Medical Sciences*, 6(2015)25-32.
- Rehder SC, "Solid-state Transformations Induced by Pharmaceutical Processes During Manufacturing," Ph.D. Thesis, University of Hamburg, Hamburg, Germany, 2013.
- Rodríguez-Hornedo N, Nehm SJ, Seefeldt KF, Pagan-Torres Y, and Falkiewicz CJ, "Reaction Crystallization of Pharmaceutical Molecular Complexes," *Molecular Pharmaceutics*, 3(2006)362-367.
- Rosenblum SB, Huynh T, Afonso A, Davis HR, Yumibe N, Clader JW, and Burnett DA, "Discovery of 1-(4-Fluorophenyl)-3(R)-[3-(4-Fluorophenyl)-3(S)-Hydroxy-

- Propyl]-4(S) (4-Hydroxy Phenyl)-2-Azetidinone (SCH 58235): a Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption,” *Journal of Medicinal Chemistry*, 41(1998)973-980.
- Rowe RC, Sheskey PJ and Quinn ME. Handbook of Pharmaceutical Excipients, Pharmaceutical Press, London, UK, 2009.
- Sakaeda T, Okamura N, Nagata S, Yagami T, Horinouchi M, Okumura K, Yamashita F, and Hashida M, “Molecular and Pharmacokinetic Properties of 222 Commercially Available Oral Drugs in Humans,” *Biological and Pharmaceutical Bulletin*, 24(2001)935-940.
- Salazar J, “Combinative Particle Size Reduction Technologies for the Formulation of Poorly Soluble Drugs,” Ph.D. Thesis, University of Berlin, Berlin, Germany, 2013.
- Sami F, Philip B, and Pathak K, “Effect of Auxiliary Substances on Complexation Efficiency and Intrinsic Dissolution Rate of Gemfibrozil- β -CD Complexes,” *AAPS PharmSciTech*, 11(2010)27-35.
- Sanphui P and Rajput L, “Tuning Solubility and Stability of Hydrochlorothiazide Co-Crystals,” *Acta Crystallographica B*, 70(2014)81-90.
- Schmidt BVKJ, “Novel Macromolecular Architectures via a Combination of Cyclodextrin Host/Guest Complexation and RAFT Polymerization,” Ph.D. Thesis, Karlsruhe Institute of Technology, Karlsruhe, Germany, 2013.
- Schmidt M, Kusche R, von Issendorff B, and Haberland H, “Irregular Variations in the Melting Point of Size-Selected Atomic Clusters,” *Nature*, 393(1998)238-240.
- Schultheiss N and Newman A, “Pharmaceutical Cocrystals and their Physicochemical Properties,” *Crystal Growth & Design*, 9(2009)2950-2967.
- Selic L and Ham Z, EP Patent No. 1939174 A1, 2008.
- Shah AK and Agnihotri SA, “Recent Advances and Novel Strategies in Pre-clinical Formulation Development: An Overview,” *Journal of Controlled Release*, 156(2011)281-296.
- Shah M, Pore Y, Dhawale S, Burade K, and Kuchekar B, “Physicochemical Characterization of Spray Dried Ternary Micro-Complexes of Cefuroxime Axetil with Hydroxypropyl- β -Cyclodextrin,” *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 76(2012)391-401.
- Shattock TR, “Crystal Engineering of Co-crystals and their Relevance to Pharmaceutical Forms,” Ph.D. Thesis, University of South Florida, Tampa, Florida, US, 2007.

- Shimpi MR, Childs SL, Boström D, and Velaga SP, “New Cocrystals of Ezetimibe with L-Proline and Imidazole,” *Crystal Engineering Communications*, 16(2014)8984-8993.
- Shiraki K, Takata N, Takano R, Hayashi Y, and Terada K, “Dissolution Improvement and the Mechanism of the Improvement from Cocrystallization of Poorly Water-Soluble Compounds,” *Pharmaceutical Research*, 25(2008)2581-2592.
- Sigfridsson K, Forssen S, Hollander P, Skantze U, and de Verdier J, “A Formulation Comparison, using a Solution and Different Nanosuspensions of a Poorly Soluble Compound,” *European Journal of Pharmaceutics and Biopharmaceutics*, 67(2007)540-547.
- Simperler A, Watt SW, Bonnet PA, Jones W, and Motherwell WDS, “Correlation of Melting Points of Inositols with Hydrogen Bonding Patterns,” *Crystal Engineering Communications*, 8(2006)589-600.
- Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, and Rao PS. Optimization of Formulation and Process Variable of Nanosuspension: An Industrial Perspective” *International Journal of Pharmaceutics*,” 402(2010)213-220.
- Sinha VR, Anitha R, Ghosh S, Nanda A, and Kumria R, “Complexation of Celecoxib with β -Cyclodextrin Characterization of the Interaction in Solution and in Solid State,” *Journal of Pharmaceutical Sciences*, 94(2005)676-687.
- Soares-Sobrinho JL, Santos FLA, Lyra MAM, Alves LDS, Rolim LA, Lima AAN, Nunes LCC, Soares MFR, Rolim-Neto PJ, and Torres-Labandeira JJ, “Benzimidazole Drug Delivery by Binary and Multicomponent Inclusion Complexes using Cyclodextrins and Polymers, *Carbohydrate Polymers*, 89(2012)323-330.
- Srivalli KMR and Lakshmi PK, “Overview of P-glycoprotein Inhibitors: a Rational Outlook,” *Brazilian Journal of Pharmaceutical Sciences*, 48(2012)353-367.
- Srivalli KMR and Mishra B, “Drug Nanocrystals: A Way toward Scale-up,” *Saudi Pharmaceutical Journal*, (2014). Accepted for publication on 26 April 2014, Available online since 9 May 2014 (<http://dx.doi.org/10.1016/j.jsps.2014.04.007>).
- Srivalli KMR and Mishra B, “Drug Nanocrystals: Four Basic Prerequisites for Formulation Development and Scale-up,” *Current Drug Targets*, 16(2015a)136-147.
- Srivalli KMR and Mishra B, “Preparation and Pharmacodynamic Assessment of Ezetimibe Nanocrystals: Effect of P-gp Inhibitory Stabilizer on Particle Size and Oral Absorption,” *Colloids and Surfaces B: Biointerfaces*, 135(2015b)756-764.

- Srivalli KMR and Mishra B, "Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl- β -Cyclodextrin and Hydrophilic Auxiliary Substances," *AAPS PharmSciTech*, 17(2016)272-283.
- Stanton M and Bak A, "Physicochemical Properties of Pharmaceutical Cocrystals: a Case Study of Ten AMG 517 Co-Crystals," *Crystal Growth & Design*, 8(2008)3856-3862.
- Stella VJ and Quanrenhe, "Cyclodextrins," *Toxicologic Pathology*, 36(2008)30-42.
- Stella VJ and Rajewski RA, "Cyclodextrins: their Future in Drug Formulation and Delivery," *Pharmaceutical Research*, 14(1997)556-567.
- Subrahmanyam CVS, Textbook of Physical Pharmaceutics, Vallabh Prakashan, New Delhi, India, 2000.
- Suchy D, Łabuzek K, Pierzchała O, and Okopień B, "RP-HPLC–UV Determination of Ezetimibe in Serum: Method Development, Validation and Application to Patients Chronically Receiving the Drug," *Acta Chromatographica*, 25(2013)483-502.
- Sugandha K, Kaity S, Mukherjee S, Isaac J, and Ghosh A, "Solubility Enhancement of Ezetimibe by a Cocrystal Engineering Technique," *Crystal Growth & Design*, 14(2014)4475-4486.
- Szejtli J, "Past, Present, and Future of Cyclodextrin Research," *Pure and Applied Chemistry*, 76(2004)1825-1845.
- Taupitz T, Dressman JB, and Klein S, "New Formulation Approaches to Improve Solubility and Drug Release from Fixed Dose Combinations: Case Examples Pioglitazone/Glimepiride and Ezetimibe/Simvastatin," *European Journal of Pharmaceutics and Biopharmaceutics*, 84(2013)208-218.
- Thakuria R, Deloria A, Jones W, Lipert MP, Roy L, and Rodríguez-Hornedo N, "Pharmaceutical Cocrystals and Poorly Soluble Drugs," *International Journal of Pharmaceutics*, 453(2013)101-125.
- Thayer AM, "Finding Solutions," *Chemical & Engineering News*, 88(2010)13-18.
- Trask AV, "An Overview of Pharmaceutical Cocrystals as Intellectual Property," *Molecular Pharmaceutics*, 4(2007)301-309.
- USFDA dissolution guidelines and methods. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1. Last accessed 08 October 2015.

- Valero M, Perez-Revuelta BI, and Rodriguez LJ, "Effect of PVPK-25 on the Formation of the Naproxen: Beta-Cyclodextrin Complex," *International Journal of Pharmaceutics*, 253(2003)97-110.
- Valle EMM, "Cyclodextrins and their Uses: a Review," *Process Biochemistry*, 39(2004)1033-1046.
- Varma MVS and Panchagnula R, "Enhanced Oral Paclitaxel Absorption with Vitamin E-TPGS: Effect on Solubility and Permeability In vitro, In situ and In vivo," *European Journal of Pharmaceutical Sciences*, 25(2005)445-453.
- Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, Durst GL, and Hipskind PA, "Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs," *Journal of Medicinal Chemistry*, 47(2004)224-232.
- Vishweshwar P, McMahon JA, Bis JA and Zaworotko MJ, "Pharmaceutical Co-crystals," *Journal of Pharmaceutical Sciences*, 95(2006)499-516.
- Wang BH, Zhang WB, and Zhang W, "Progress in Drying Technology for Nanomaterials," *Drying Technology*, 23(2005)7-32.
- Wang D, Li H, Gu J, Guo T, Yang S, Guo Z, Zhang X, Zhu W, and Zhang J, "Ternary System of Dihydroartemisinin with Hydroxypropyl- β -Cyclodextrin and Lecithin: Simultaneous Enhancement of Drug Solubility and Stability in Aqueous Solutions," *Journal of Pharmaceutical and Biomedical Analysis*, 83(2013)141-148.
- Wang J, Su B, Su Y, Yang Y, and Ren Q, "LC Separation and Quantification of Tocopheryl Polyethylene Glycol Succinate and Tocopheryl Acid Succinate in TPGS Reaction Mixture," *Chromatographia*, 70(2009)551-555.
- Wenlock MC, Austin RP, Barton P, Davis AM, and Leeson PD, "A Comparison of Physicochemical Property Profiles of Development and Marketed Oral Drugs," *Journal of Medicinal Chemistry*, 46(2003)1250-1256.
- WHO Expert Committee on Specifications for Pharmaceutical Preparation. WHO Technical Report Series 953. Forty-third Report, 2009. Available from: http://www.who.int/medicines/publications/pharmprep/pdf_trs953.pdf. Last accessed on 14 February 2016.
- WHO model lists of essential medicines. Available from: <http://www.who.int/medicines/publications/essentialmedicines/en/>. Last accessed on 14 February 2016
- Wu H, Liang H, Yuan Q, Wang T, Yan X, "Preparation and Stability Investigation of the Inclusion Complex of Sulforaphane with Hydroxypropyl- β -Cyclodextrin," *Carbohydrate Polymers*, 82(2010)613-617.

Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K, Higgins R, Batra U, Shelukar S, Kwei G, and Storey D, "The Role of Biopharmaceutics in the Development of a Clinical Nanoparticle Formulation of MK-0869: a Beagle Dog Model Predicts Improved Bioavailability and Diminished Food Effect on Absorption in Human," *International Journal of Pharmaceutics*, 285(2004)135-146.

www.cyclolab.hu. Last accessed on 13 February 2016.

Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, and Cui F, "Preparation of Stable Nitrendipine Nanosuspensions using the Precipitation-Ultrasonication Method for Enhancement of Dissolution and Oral Bioavailability," *European Journal of Pharmaceutical Sciences*, 40(2010)325-334.

Yadav AV, Dabke AP, and Shete AS, "Crystal Engineering to Improve Physicochemical Properties of Mefloquine Hydrochloride," *Drug Development and Industrial Pharmacy*, 36(2010)1036-1045.

Yadav D, Yadav A, Karekar P, Pore Y, and Gajare P, "Enhanced Solubility and Dissolution Rate of Olmesartan Medoxomil using Crystallo-Co-Agglomeration Technique," *Der Pharmacia Sinica*, 3(2012)160-169.

Yan Y, "Exploring And Analysing The Structural Diversity Of Organic Co-Crystals," Ph.D. Thesis, Cardiff University, Wales, UK, 2014.

Yue P, Wan J, Wang Y, Li Y, Ma Y, Yang M, Hub P, Yuan H, and Wang C, "D-Alpha-Tocopherol Acid Polyethylene Glycol 1000 Succinate, an Effective Stabilizer during Solidification Transformation of Baicalin Nanosuspensions," *International Journal of Pharmaceutics*, 443(2013)279-287.

Yuvaraja K and Khanam J, "Enhancement of Carvedilol Solubility by Solid Dispersion Technique using Cyclodextrins, Water Soluble Polymers and Hydroxyl Acid," *Journal of Pharmaceutical and Biomedical Analysis*, 96(2014)10-20.

Zeng J, Ren Y, Zhou C, Yu S, and Chen W, "Preparation and Physicochemical Characteristics of the Complex of Edaravone with Hydroxypropyl- β -Cyclodextrin," *Carbohydrate Polymers*, 83(2011)1101-1105.

Zetia Prescribing Information, North Wales, PA, Merck/Schering-Plough Pharmaceuticals, 2002. Available from: https://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf. Last accessed on 28 September 2015.

Zhang GGZ, Henry RF, Borchardt TB, and Lou X, "Efficient Cocrystal Screening using Solution-Mediated Phase Transformation," *Journal of Pharmaceutical Sciences*, 96(2007)990-995.

Zhang J, Huang Y, Liu D, Gao Y, and Qian S, "Preparation of Apigenin Nanocrystals using Supercritical Antisolvent Process for Dissolution and Bioavailability

Enhancement,” *European Journal of Pharmaceutical Sciences*, 48(2013)740-747.

Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, and Hovgaard L, “Adsorption of Pharmaceutical Excipients onto Microcrystals of Siramesine Hydrochloride: Effects on Physicochemical Properties,” *European Journal of Pharmaceutics and Biopharmaceutics*, 71(2009)109-116.

Zoeller T, Dressman JB, and Klein S, “Application of a Ternary HP- β -CD-Complex Approach to Improve the Dissolution Performance of a Poorly Soluble Weak Acid Under Biorelevant Conditions,” *International Journal of Pharmaceutics*, 430(2012)176-183.

